199 related articles for article (PubMed ID: 29720705)
41. Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.
Heidenreich S; Ziagkos D; de Wreede LC; van Biezen A; Finke J; Platzbecker U; Niederwieser D; Einsele H; Bethge W; Schleuning M; Beelen DW; Tischer J; Nagler A; Glass B; Maertens J; Yáñez L; Beguin Y; Sill H; Scheid C; Stelljes M; Ganser A; Zachée P; Selleslag D; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2017 Jan; 23(1):44-52. PubMed ID: 27720995
[TBL] [Abstract][Full Text] [Related]
42. Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT).
Schetelig J; de Wreede LC; Andersen NS; Moreno C; van Gelder M; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Schaap N; Wagner E; Henseler A; van Biezen A; Bornhäuser M; Iacobelli S; Putter H; Schönland SO; Kröger N;
Br J Haematol; 2017 Aug; 178(4):521-533. PubMed ID: 28589551
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.
Mukherjee S
Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911
[No Abstract] [Full Text] [Related]
44. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
[TBL] [Abstract][Full Text] [Related]
45. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019.
Duarte RF; Labopin M; Bader P; Basak GW; Bonini C; Chabannon C; Corbacioglu S; Dreger P; Dufour C; Gennery AR; Kuball J; Lankester AC; Lanza F; Montoto S; Nagler A; Peffault de Latour R; Snowden JA; Styczynski J; Yakoub-Agha I; Kröger N; Mohty M;
Bone Marrow Transplant; 2019 Oct; 54(10):1525-1552. PubMed ID: 30953028
[TBL] [Abstract][Full Text] [Related]
46. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations.
Aljurf M; Weisdorf D; Hashmi SK; Nassar A; Gluckman E; Mohty M; Rizzo D; Pasquini M; Hamadani M; Saber W; Hari P; Kharfan-Dabaja M; Majhail N; Gerges U; Hamidieh AA; Hussain F; Elhaddad A; Mahmoud HK; Tbakhi A; Othman TB; Hamladji RM; Bekadja MA; Ahmed P; Bazarbachi A; Adil S; Alkindi S; Ladeb S; Dennison D; Patel M; Lu P; Quessar AE; Okamoto S; Atsuta Y; Alhejazi A; Ayas M; Ahmed SO; Novitzky N; Srivastava A; Seber A; Elsolh H; Ghavamzadeh A; Confer D; Kodera Y; Greinix H; Szer J; Horowitz M; Niederwieser D
Hematol Oncol Stem Cell Ther; 2020 Mar; 13(1):7-16. PubMed ID: 31449781
[TBL] [Abstract][Full Text] [Related]
47. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).
Lazarevic VL; Labopin M; Depei W; Yakoub-Agha I; Huynh A; Ljungman P; Schaap N; Cornelissen JJ; Maillard N; Pioltelli P; Gedde-Dahl T; Lenhoff S; Houhou M; Esteve J; Mohty M; Nagler A
Am J Hematol; 2018 Jan; 93(1):31-39. PubMed ID: 28971504
[TBL] [Abstract][Full Text] [Related]
48. Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).
Worel N; Ljungman P; Verheggen ICM; Hoogenboom JD; Knelange NS; Eikema DJ; Sánchez-Ortega I; Riillo C; Centorrino I; Averbuch D; Chabannon C; de la Camara R; Kuball J; Ruggeri A
Bone Marrow Transplant; 2023 Dec; 58(12):1348-1356. PubMed ID: 37673982
[TBL] [Abstract][Full Text] [Related]
49. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP).
Michallet M; Thiébaut A; Dreger P; Remes K; Milpied N; Santini G; Hamon M; Björkstrand B; Kimby E; Belhabri A; Tanguy ML; Apperley JF
Br J Haematol; 2000 Mar; 108(3):595-601. PubMed ID: 10759719
[TBL] [Abstract][Full Text] [Related]
50. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
[TBL] [Abstract][Full Text] [Related]
51. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
Halaburda K; Labopin M; Houhou M; Niederwieser D; Finke J; Volin L; Maertens J; Cornelissen JJ; Milpied N; Stuhler G; Kröger N; Esteve J; Mohty M; Nagler A
Bone Marrow Transplant; 2018 Jun; 53(6):683-691. PubMed ID: 29670208
[TBL] [Abstract][Full Text] [Related]
52. Indications and donor source of hematopoietic stem cell transplants in Europe 1993: report from the European Group for Blood and Marrow Transplantation (EBMT).
Gratwohl A; Hermans J
Clin Transplant; 1995 Oct; 9(5):355-63. PubMed ID: 8541627
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
Poiré X; Labopin M; Maertens J; Yakoub-Agha I; Blaise D; Ifrah N; Socié G; Gedde-Dhal T; Schaap N; Cornelissen JJ; Vigouroux S; Sanz J; Michaux L; Esteve J; Mohty M; Nagler A
J Hematol Oncol; 2017 Jan; 10(1):20. PubMed ID: 28100265
[TBL] [Abstract][Full Text] [Related]
54. Investigation and Management of Bone Mineral Density Following Hematopoietic Cell Transplantation: A Survey of Current Practice by the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation.
Salooja N; Greinix H; Ruutu T; van der Werf S; van Biezen A; Lawitschka A; Basak G; Duarte R
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1955-1962. PubMed ID: 32623077
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas.
Heinzelmann F; Bethge W; Beelen DW; Engelhard M; Kröger N; Dreger P; Niederwieser D; Finke J; Bunjes D; Tischer J; Kobbe G; Holler E; Bornhäuser M; Stelljes M; Baurmann H; Müller A; Haubitz I; Schrezenmeier H; Müller C; Ottinger H
Bone Marrow Transplant; 2016 May; 51(5):654-62. PubMed ID: 26855152
[TBL] [Abstract][Full Text] [Related]
56. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
[TBL] [Abstract][Full Text] [Related]
57. No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Cahn JY; Labopin M; Sierra J; Blaise D; Reiffers J; Ferrant A; Bergmann L; Visani G; Cornelissen J; De Witte T; Bosi A; Frassoni F; Gorin NC
Br J Haematol; 2000 Aug; 110(2):308-14. PubMed ID: 10971386
[TBL] [Abstract][Full Text] [Related]
58. Rapid full engraftment and successful immune reconstitution after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in Omenn syndrome.
Gozdzik J; Czogala W; Skoczen S; Krasowska-Kwiecien A; Wiecha O; Mordel A; Lesko E; Majka M; Kowalczyk D; Zembala M
Pediatr Transplant; 2009 Sep; 13(6):760-5. PubMed ID: 18992055
[TBL] [Abstract][Full Text] [Related]
59. [Bone marrow transplantation in the treatment of autoimmune disease].
Farge D
Rev Med Interne; 2007 Dec; 28 Suppl 4():S285-7. PubMed ID: 17980463
[No Abstract] [Full Text] [Related]
60. Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Markova M; Barker JN; Miller JS; Arora M; Wagner JE; Burns LJ; MacMillan ML; Douek D; DeFor T; Tan Y; Repka T; Blazar BR; Weisdorf DJ
Bone Marrow Transplant; 2007 Feb; 39(4):193-9. PubMed ID: 17220905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
